Vera Therapeutics (VERA) has released an update to notify the public and investors about a regulation fd disclosure.
Vera Therapeutics, Inc. announced positive 72-week results from the open label extension of its Phase 2b ORIGIN clinical trial, which evaluated the efficacy of atacicept in treating patients with immunoglobulin A nephropathy. Alongside the announcement, the company released a presentation detailing the trial’s findings.
For further insights into VERA stock, check out TipRanks’ Stock Analysis page.
